Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients

Key Points

• The central aim is to evaluate the clinical efficacy of pharmacogenomic-guided treatment in schizophrenia patients.
• Investigated hospitalized patients diagnosed with schizophrenia.
• Applied combinatorial pharmacogenomics (CPGx) to guide treatment decisions.
• Significant improvement in treatment outcomes with CPGx guidance in schizophrenia patients.